CJC-1295 and ipamorelin: can this peptide pair build muscle and burn fat?

CJC-1295 and ipamorelin are lab-made peptides that prompt your body to release more growth hormone. People ask about them together for muscle, fat loss and sleep. Small studies show they raise growth hormone levels, but no trial has shown those benefits in people, and we found none testing the pair. Neither is covered by the 2026 HHS peptide policy. A physician can help with options tested in people.

Reviewed by Darshan Patel, MD, Obesity medicine physician, on 2026-11-12. Next review 2026-12-12.

Book my consultation Video consultations with an Aayu Well physician. Most major insurance accepted, plus convenient cash pay options.

Why people are curious about CJC-1295 and ipamorelin

People look into this pair hoping for more muscle, less fat, deeper sleep and faster recovery. Both work by prompting your own pituitary gland to release more growth hormone. CJC-1295 is a long-acting, lab-made version of the hormone that signals that release. Ipamorelin acts like ghrelin, another of the body's signals for growth hormone.

Wanting to stay strong and lean is a great goal. The real question is whether these peptides are the best way to get there.

What the research shows so far

Evidence grade D: early. Studies measure hormone levels, not the results people want. How we grade evidence.

• CJC-1295 in healthy adults: in two placebo-controlled studies lasting four and seven weeks, a single shot raised growth hormone for six days or more and IGF-1, a growth factor made in response, for over a week. No serious reactions were reported. These studies measured hormone levels, not muscle, fat or sleep.
• Ipamorelin: most of what we know comes from animal studies. Its largest human trial, in 117 adults recovering from bowel surgery, found it well tolerated but no better than placebo at bringing back normal eating.
• Together: we didn't find a published study testing the two together in people.
• Still open: whether either one helps muscle, fat loss, sleep or recovery in a proper trial, and what they do over months or years. A 2026 review of peptides sold directly to patients found rigorous human safety data scarce.

Your goal, with stronger evidence behind it

Most people who ask about this pair want more muscle, less fat and better sleep. Here's what has been tested in people.

• Keep your muscle while you lose fat. In a 6-month trial of 160 older adults losing weight, those who added strength training lost less muscle than those who only did aerobic exercise, and aerobic plus strength work improved physical function the most. At Aayu Well, a registered dietitian helps you build meals that support your muscle.
• Lose the weight that's slowing you down. For people living with obesity, GLP-1 medicines such as semaglutide and tirzepatide have been tested in large trials with thousands of adults. They led to far more weight loss than placebo and improved heart and metabolic health numbers.
• Sleep better. For adults with obesity and moderate to severe obstructive sleep apnea, two year-long trials found tirzepatide cut breathing interruptions during sleep far more than placebo.

Aayu Elevate™ puts this together: video visits with an obesity medicine physician, a registered dietitian, and medicine when it's right for you. Most major insurance accepted, plus convenient cash pay options. Book my consultation

Are CJC-1295 and ipamorelin legal now?

Neither is part of the October 2026 HHS policy, which covers six other peptides and doesn't reach peptides outside its list. Both were once in FDA's category for compounding ingredients with significant safety risks; the nominations that could have added them to the pharmacy list were later withdrawn. Ipamorelin stays in that category for outsourcing facilities. We found no FDA-approved drug containing either one. See which peptides can be compounded.

Good to know before you try them

• No one has followed people taking these peptides for months or years, and FDA says clinical data on CJC-1295 are limited.
• FDA has noted serious side effects reported with CJC-1295, including a faster heart rate and a reaction that widens blood vessels. For ipamorelin, FDA points to a published report of serious side effects, including a death, when it was given by IV to help the gut move.
• FDA also warns that compounded CJC-1295 and ipamorelin may set off an immune reaction when given in some ways.
• Talk with your physician first if you have diabetes: tesamorelin, an approved medicine that works in a similar way to CJC-1295, can raise blood sugar.
• Both are banned in sport at all times, so athletes who are drug tested should skip them.
• Products labeled research use only aren't made or tested for people. Here's why that label matters.

Where Aayu Well stands

We don't prescribe CJC-1295 or ipamorelin right now. We're following the research and the pharmacy rules closely, and we review this page every month.

What we can help with today is usually what sits behind the question: weight, muscle, energy, sleep and mood. Bring your peptide questions to your first visit. Your physician will give you a straight answer and a plan built around you.

Questions people ask

Can I talk to an Aayu Well physician about peptides?

Yes, and we'd encourage it. Bring your questions to your visit. We don't prescribe CJC-1295 or ipamorelin right now, but your physician will go over the evidence with you, review everything you take, and build a plan for the goal behind the question, whether that's muscle, weight, energy or sleep.

Are CJC-1295 and ipamorelin legal?

As of November 12, 2026, neither is one of the six peptides in the October 2026 HHS policy, and neither is on FDA's list of ingredients formally added for pharmacy compounding. Both were once in FDA's category for compounding ingredients with significant safety risks before their nominations were withdrawn. We found no FDA-approved drug containing either one.

Is CJC-1295 with ipamorelin safe?

It hasn't been studied enough to say. FDA has noted serious side effects reported with CJC-1295, including a faster heart rate, and a published report of serious side effects, including a death, when ipamorelin was given by IV. No one has followed people using the pair for months or years.

Is this the same as taking growth hormone?

No. Growth hormone shots replace the hormone directly. These peptides prompt your pituitary gland to release more of its own. In a study of healthy men aged 20 to 40, the body's natural pulses of growth hormone continued while CJC-1295 raised the overall level.

Can I take them with a GLP-1 like Wegovy or Zepbound?

We haven't found studies of these peptides with a GLP-1, so it's worth a conversation first. Tell the physician who prescribes your GLP-1 about any peptide you use.

Are CJC-1295 and ipamorelin banned in sports?

Yes. The World Anti-Doping Agency's 2026 list prohibits both at all times, in and out of competition, so athletes who are drug tested should skip them.

Sources

1. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026)
2. Federal Register notice FR Doc. 2026-22192, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (October 30, 2026)
3. Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (November 4, 2026)
4. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A
5. DailyMed (National Library of Medicine) label search: ipamorelin, no drug labels found (checked November 12, 2026)
6. DailyMed (National Library of Medicine) label search: CJC-1295, no human drug label found (checked November 12, 2026)
7. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
9. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
10. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534.
11. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935.
12. EGRIFTA WR (tesamorelin) prescribing information, DailyMed (updated July 29, 2026)
13. Villareal DT, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943-1955.
14. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
15. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
16. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205.
17. German Sport University Cologne: WADA 2026 Prohibited List, S2 peptide hormones, growth factors, related substances and mimetics